Cutaneous T-cell lymphomas (CTCL) are rare diseases that, in their advanced stages or in transformation, have a poor prognosis. Autologous stem cell transplantation (Au-SCT) after high-dose therapy has yielded disappointing results. Allogeneic transplantation (allo-SCT) provides the potential advantage of an immune-mediated graftversus-lymphoma (GVL) effect. Reduced-intensity allo-SCT potentially offers a GVL effect, but with diminished toxicity related to the induction regimen; however, published experience with this approach in CTCL is limited. We report a series of three patients (age 35-49) with advanced, refractory (n ¼ 2) or transformed (n ¼ 1) CTCL who underwent reduced-intensity allo-SCT in the context of active disease. All three survived the peritransplant period and, despite later having disease relapse, all exhibited evidence of a GVL effect. Relapses of the disease were in the context of immune suppression for graft-versus-host disease (GVHD), and when immune suppression was reduced, responses were regained. A comparison is made of these results to those in a review of the published literature to date. We conclude that while a GVL can be achieved for CTCL with reduced-intensity allogeneic transplantation, the clinical benefits are short lived and novel approaches are required to obtain sustained remissions.
The cutaneous T-cell lymphomas (CTCL) are an uncommon group of diseases, which usually follow an indolent course. Mycosis fungoides (MF) is the most common subtype of cutaneous lymphoma, 1 but still accounts for only 0.5% of all NHL. 2 It is usually a relapsing and remitting disease, manifested by skin patches and plaques, for which many treatment options are available. While the median survival for patients with limited patch lesions is equivalent to an age-matched population, the disease can present as, or progress to plaque or tumour stage lesions, erythroderma, extracutaneous or leukemic involvement (Se´zary Syndrome/SS). Patients with advanced-stage disease have a poor prognosis of only 2-4 years. 3, 4 Furthermore, in 40% of patients with indolent CTCL, the disease can transform to a diffuse large cell phenotype carrying a particularly grave prognosis. 5, 6 Therapy options for advanced-stage CTCL predominantly involve systemic approaches including immunomodulators such as interferon alpha, extracorporeal photopheresis (ECP), single or combination agent chemotherapy, oral retinoids, and immunotherapy such as alemtuzumab 6, 7 or denileukin diftitox. 7, 8 However, for patients with adverse prognostic factors, all of these approaches provide only limited-duration remissions, and the overall pattern is that of repeated relapse, and often death from complications of therapy or refractory disease.
Despite the theoretical advantage of high-dose chemotherapy and autologous stem cell transplantation (Au-SCT), the results have been disappointing in advancedstage CTCL. The majority of patients achieve remission but often relapse early post transplant. [9] [10] [11] [12] The use of allogeneic stem cell transplantation (allo-SCT) may offer an immune mediated graft-versus-lymphoma (GVL) effect, 10 where the adoptive transfer of donor leukocytes in the allograft may lead to immunologic recognition of recipient tumour cells as 'non-self'. Indeed, there is increasing evidence that the growth of CTCL can be influenced by immunoregulatory T-cells. 13 Moreover, it has been postulated that the effect of ECP in SS is through the generation of tumour-specific immunity, following apoptosis of malignant T cells. 14 Other investigators have explored the use of allogeneic transplantation in CTCL (Table 1 ) and allogeneic T-cells have been recognized in the recipient's skin lesions. Although allo-SCT offers the potential advantages of a GVL effect, along with a graft that is uncontaminated by tumour cells, the peri-transplant mortality and morbidity is relatively high, especially in patients with CTCL where there is a particularly high risk of infection. Thus, we were interested in examining the role of reduced-intensity conditioning in patients with relapsed/ refractory CTCL. 23, 24 Here, we describe three heavily pretreated patients with advanced-stage refractory CTCL, who received allo-SCT with reduced-intensity conditioning.
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Patients and methods
Patient 1
A 35-year-old man was diagnosed with stage Ib MF (plaque/patch-stage involving 410% of body surface area) in 1997. His disease was only transiently responsive to topical steroids, psoralen plus Ultra Violet-A (PUVA), mechlorethamine, bexarotene, total skin electron beam (TSEB) therapy, combination chemotherapy with CVP (cyclophosphamide, vincristine, prednisolone), CHOP chemotherapy with PUVA, liposomal doxorubicin, high-dose methotrexate, and alemtuzumab. Autologous stem cells were collected and stored. A skin biopsy prior to transplant demonstrated MF with no evidence of large cell transformation. In March 2000, in the context of extensive and refractory disease, he underwent an HLA-identical, sibling reduced-intensity bone marrow allograft with fludarabine (25 mg/m 2 /day, day À6 to À2) and melphalan (140 mg/m 2 day À2) conditioning. Graft-verus-host disease (GVHD) prophylaxis consisted of cyclosporine. He developed early grade II gut GVHD on day 15, and immune suppression was increased. His MF lesions flared, but on weaning of the steroids, he achieved remission of his MF at day 32. Significant cutaneous GVHD developed, responding to an increase in steroids. The MF lesions progressed at 4 months, but they regressed and healed in response to reduction of cyclosporine and prednisolone. At 8 months he had a serious flare of conjunctival GVHD, which required an increased dose of methylprednisolone and cyclosporine. At 13 months post transplant, there was a further biopsy-proven cutaneous relapse of MF, which responded to reduction in immunosuppression. At 24 months post transplant, there was progressive skin disease (Figure 1) , which was treated with dose-escalating donor lymphocyte infusions (DLI -starting dose 5.0 Â 10 6 /kg CD3 þ cells). Each DLI achieved a definite response with necrosis of the MF lesions with concurrent oral GVHD; however, these responses were nonsustained. After the third DLI, interferon alpha was added in an attempt to enhance the GVL effect. This induced only very mild GVHD with a brief improvement in MF, but new lesions soon appeared. A fourth DLI (1 Â 10 8 /kg CD3 þ cells) was later given due to progressive disease. This induced significant GVHD, and a dramatic inflammatory reaction in the MF lesions followed by the definite regression of these lesions (Figure 2 ). His immune suppression is currently being weaned in the context of minimal stable low-grade MF.
Patient 2
A 49-year-old man with Se´zary Syndrome initially responded to PUVA, but later developed progressive BM involvement, increasing circulating Se´zary cells, and lymph node involvement. He relapsed after four cycles of highdose methotrexate (1 g/m 2 ) and again just 2 months after TSEB. His disease was refractory to liposomal doxorubicin. Autologous PBPC were collected and stored following high-dose cyclophosphamide 4 g/m 2 (which induced a transient remission). Pre-transplant, there was relapsed, refractory disease, but no histologic evidence of transformation. He underwent a fludarabine (25 mg/m 2 /day, day À6 to À2) and melphalan (140 mg/m 2 day À2) reducedintensity HLA-identical sibling bone marrow allograft in September 1999. Skin biopsy pre-transplant showed persistent CTCL with no evidence of large cell transformation. GVHD prophylaxis consisted of cyclosporine alone. Within 3 weeks, there was brisk and marked necrosis of his skin lesions. He subsequently developed mild cutaneous and conjunctival GVHD, but his MF/SS was well controlled. On day 43 his MF/SS relapsed with biopsy-proven disease. Cyclosporine was withdrawn, with subsequent partial remission. The emergence of cutaneous GVHD required addition of steroids on day 88 and he had a further MF/SS relapse at 4 months that was treated with DLI (5 Â 10 7 CD3 þ cells/kg). This induced grade III cutaneous and oral GVHD and almost complete regression of his MF lesions. The patient died at 11 months posttransplant, with severe pneumonitis complicating progressive chronic GVHD. At the time of death there were progressive skin lesions presumed to be CTCL.
Patient 3
A 48-year-old woman with a long history of MF, since the age of 19 had experienced initial disease response to phototherapy (PUVA), and subsequently to local radiotherapy for limited nodules in 1993 and 2000. In October 2000 she developed new supraorbital, arm, buttock and perineal lesions, and axillary, inguinal and mediastinal lymphadenopathy on CT. Biopsy showed transformation to a large cell phenotype, which did not involve the bone marrow. After initially responding to two cycles of alkylator-based chemotherapy (Hyper-CVAD) 25 she relapsed with progressive large cell disease and subsequently underwent allo-SCT in January 2003. She received fludarabine (25 mg/m 2 /day, day À6 to À2) and melphalan (140 mg/m 2 day À2) conditioning and an HLA-identical sibling allograft with G-CSF-mobilised peripheral blood progenitor cells (PBPC). GVHD prophylaxis consisted of cyclosporine and a short course of methotrexate. After initial disease response, she had a limited cutaneous relapse of MF (with low-grade disease), 4 months post-allograft. Cyclosporine was ceased, resulting in regression of her skin lesions in the context of mild cutaneous, oral and hepatic chronic GVHD. At 6 months post-allograft, she developed new cutaneous lesions, which on biopsy showed a dense infiltrate of large cells, consistent with a relapse of her highgrade disease. There was no evidence of the previous MF. These lesions progressed slowly initially but subsequently progressed more quickly. Salvage therapy with gemcitabine, vinorelbine and ifosfamide has achieved a clinical complete remission.
Discussion
To date, there have been few reported cases of allogeneic transplantation for advanced-stage or refractory CTCL ( Table 1 ). The goal of treating our patients using reducedintensity allo-SCT was to achieve a GVL effect while limiting toxicity. Although our patients were relatively young, they had aggressive skin disease and were at highrisk of peri-transplant infection. After our initial observation of a positive GVL effect in the first patient following reduced-intensity allo-SCT, we elected to pursue the same strategy in the subsequent two patients who were somewhat less heavily pre-treated.
Although the existence of GVL in low-grade NHL remains controversial, 26 the three cases reported here provide support for the existence of a GVL effect in CTCL. In each patient, there was evidence of disease regression either following reduction of immunosuppression or following DLI. These findings are not dissimilar to the reports of regression of B-cell NHL after reduction or withdrawal of immune suppression, or after donor lymphocyte infusion. [27] [28] [29] Although it is possible that the initial disease response seen in our patients was due to the conditioning regimen, the late responses occurred many months after their administration and were temporally closely related to reduction in immunosuppression and/or administration of DLI. It is of interest that case 3 relapsed with her previously recognized large cell, transformed disease, rather than low-grade CTCL. We postulate that this may be a result of the low-grade disease being a better target for the GVL effect, a situation not dissimilar to that seen with B-cell NHL. [27] [28] [29] Despite demonstrating a clinical GVL effect, in all patients the period of disease remission was brief, indicating that there was insufficient GVL effect to control the disease. Thus, we believe that although the use of allo-SCT in CTCL is promising, substantial improvements need to be made. Firstly, all our patients had refractory disease with multiple prior relapses. We believe that if allo-SCT is to be considered for patients with advanced disease (ie in stage III/IV or transformed disease), it should be used relatively early in the disease course. Secondly, although reducedintensity allo-SCT potentially reduces treatment toxicity, one of our patients died of the complications of GVHD. Thus, further improvements to control the severity of GVHD need to be pursued, particularly in a group of patients at high risk of infection. Lastly, the disease bulk in these patients may have been too substantial for a GVLeffect to control the disease.
Although we and others have demonstrated a GVL effect in CTCL with melphalan/fludarabine conditioning, 20,21 we do not feel that this strategy alone is optimum for patients with actively relapsed CTCL. Indeed, the prior reports of durable remissions, with at least equivalent mortality rates, with 'full-intensity' conditioning incorporating total body irradiation (TBI), are compelling. [15] [16] [17] [18] Thus, we would recommend that a TBI-based full-intensity allograft should still be considered in such patients. Nonetheless, one further strategy worthy of exploration may be planned auto-SCT for disease de-bulking, followed by reducedintensity allo-SCT, an approach that has proven promising in other diseases. [30] [31] [32] Moreover, in the auto-SCT phase, conditioning regimens incorporating carmustine, etoposide and cisplatin may have better remission rates than those employing TBI and cyclophosphamide. [9] [10] [11] We conclude that there appears to be a GVL effect in CTCL, acknowledging that GVHD is a difficult, 'doubleedged sword' to manage. Given that the disease remains incurable, for suitable candidates a strategy of either a fullintensity TBI-based allo-SCT or a reduced-intensity allo-SCT ensuring prior maximum tumour bulk-reduction (possibly with prior auto-SCT), needs to be considered early in the disease course. Although the literature suggests that some patients will have durable remissions, novel approaches including modification of the allo-SCT approach, and novel post-transplant therapies to prolong remission need to be explored.
